This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental and closely watched drug for multiple ...
(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...
LYON (Reuters) - Sanofi's Genzyme unit has received positive feedback from U.S. doctors after the recent launch of multiple sclerosis pill Aubagio and is moving toward refiling its FDA application for ...
Treatment of clinically isolated syndrome with oral cladribine improves clinical outcomes roughly a decade later, slowing progression to clinically definite multiple sclerosis (MS) and reducing ...
Considering the CLARITY Phase III study results, cladribine tablets may offer several improvements over existing MS drugs including a simple, short-course annual dosing regimen of either 2 or 4 weeks ...
WASHINGTON (Reuters) - The common asthma drug albuterol can help patients with multiple sclerosis, perhaps by tamping down an overactive immune system, U.S. researchers reported on Monday. The cheap ...
BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...
Hosted on MSN
Multiple sclerosis medication gap: Study finds women less likely than men to receive drugs
Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...
Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for ...
Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.
Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results